Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms

被引:15
|
作者
Kois, Abigail K. [1 ]
Nicolau, David P. [1 ]
Kuti, Joseph L. [1 ]
机构
[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06102 USA
关键词
beta-lactam/beta-lactamase inhibitor; Acinetobacter spp; carbapenemase; enterobacterales; genotypic testing Klebsiella pneumoniae carbapenemase; Pseudomonas spp; DESORPTION IONIZATION-TIME; IN-VITRO ACTIVITY; PSEUDOMONAS-AERUGINOSA INFECTIONS; FLIGHT MASS-SPECTROMETRY; POSITIVE BLOOD CULTURES; ACINETOBACTER-BAUMANNII; CEFTAZIDIME-AVIBACTAM; MULTIDRUG-RESISTANT; EXTENDED-SPECTRUM; ILL PATIENTS;
D O I
10.1097/QCO.0000000000000682
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of review Carbapenem-resistant organisms (CROs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacterales, are a threat worldwide. This review will cover mechanisms of resistance within CROs and challenges with identification and treatment of these organisms while pointing out unresolved issues and ongoing challenges. Recent findings The treatment of CROs has expanded through newer therapeutic options. Guided utilization through genotypic and phenotypic testing is necessary in order for these drugs to target the appropriate mechanisms of resistance and select optimal antibiotic therapy. Summary Identification methods and treatment options need to be precisely understood in order to limit the spread and maximize outcomes of CRO infections.
引用
收藏
页码:482 / 494
页数:13
相关论文
共 50 条
  • [1] Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram-Negative Organisms?
    Shankar, Chaitra
    Nabarro, Laura E. B.
    Anandan, Shalini
    Veeraraghavan, Balaji
    MICROBIAL DRUG RESISTANCE, 2017, 23 (04) : 437 - 446
  • [2] Treatment Options for Carbapenem-Resistant Gram-Negative Infections
    Fritzenwanker, Moritz
    Imirzalioglu, Can
    Herold, Susanne
    Wagenlehner, Florian M.
    Zimmer, Klaus-Peter
    Chakraborty, Trinad
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2018, 115 (20-21): : 345 - +
  • [3] Treatment Options for Carbapenem-Resistant Gram-Negative Infections Reply
    Chakraborty, Trinad
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2019, 116 (07): : 115 - 115
  • [5] Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
    G. L. Xia
    R. L. Jiang
    BMC Infectious Diseases, 21
  • [6] Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
    Xia, G. L.
    Jiang, R. L.
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [7] Screening for carbapenem-resistant Gram-negative bacteria
    Lee, Sang Hee
    Jeong, Seok Hoon
    Cha, Sun-Shin
    LANCET INFECTIOUS DISEASES, 2006, 6 (11): : 682 - 684
  • [8] Early identification and optimal management of carbapenem-resistant Gram-negative infection
    Bedos, J. P.
    Daikos, G.
    Dodgson, A. R.
    Pan, A.
    Petrosillo, N.
    Seifert, H.
    Vila, J.
    Ferrer, R.
    Wilson, P.
    JOURNAL OF HOSPITAL INFECTION, 2021, 108 : 158 - 167
  • [9] CLINICAL AND ECONOMIC OUTCOMES OF CARBAPENEM-RESISTANT GRAM-NEGATIVE ORGANISMS: A MULTICENTER STUDY IN CHINA
    Zhen, X.
    Gu, S.
    Sun, X.
    Hu, X.
    Gu, Y.
    Dong, H.
    VALUE IN HEALTH, 2020, 23 : S238 - S238
  • [10] Characterisation of carbapenem-resistant Gram-negative organisms from clinical specimens in Yola, Nigeria
    Shettima, Shuwaram A.
    Tickler, Isabella A.
    de la Cruz, Caitlin M.
    Tenover, Fred C.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 21 : 42 - 45